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Background 
Can the same brand name drug contain a 
different active ingredient in a different country?  
The answer to this question is, unfortunately, yes.  
With the growing trend in drug reimportation 
from other countries, differences in actual drug 
content are being discovered for the same brand 
name.  With increased travel to countries outside 
the US and Canada, greater and lengthened 
military service in foreign countries, and 
expanded use of the internet for less expensive 
prescription drugs, the possibility of acquiring a 
brand name drug with an unexpected active 
ingredient is increasing.   
The Institute for Safe Medication Practices 
(ISMP) recently reported that a patient taking 
Dilacor XR (diltiazem extended release) 120 mg 
daily for hypertension received a different product 
with the same name while traveling in Serbia.  
This patient ran out of the US prescribed product 
and obtained Dilacor from a Serbian pharmacy.  
The pharmacist filled the prescription with the 
Serbian Dilacor brand which is digoxin.  The 
patient did not notice the difference in product 
strength or appearance and continued to take the 
Serbian Dilacor.  Because the patient felt that his 
hypertension was not being controlled, he elected 
to take extra daily doses.  Three days later, he 
developed signs of digoxin toxicity, was admitted 
to an emergency facility, and treated with 
Digibind (digoxin immune FAB).1 
Dilacor is also the brand name for the 
antihypertensive agents barnidipine in Argentina 
and verapamil in Brazil.2 
 
Commentary 
This is one example of the same brand name 
being used by different manufacturers for 
different drugs in other countries.  There are 
several other examples.  Flomax (tamsulosin) for 
benign prostatic hyperplasia manufactured by 
Boehringer Ingelheim for the US and Canadian 
markets shares the same brand name, Flomax 
(morniflumate), that is used for pain, fever, or 
inflammation as manufactured by Chiesi in Italy.  
The antidepressant, Norpramin (desipramine), 
produced by Aventis, is the anti-ulcer drug, 
omeprazole (Norpramin) in Spain where it is 
produced by CEPA.  Sominex (diphenhydramine) 
is promethazine in the United Kingdom; Vivelle 
(estradiol) is ethinylestradiol, norgestimate by 
Janssen-Cilag in Austria; Fiorinal contains 
aspirin, butalbital, and caffeine but in Australia it 
is paracetamol, codeine, and doxylamine.2   
Foreign over-the-counter (OTC) brand 
products may not be the same and may even have 
the same brand name as a prescription product.  
Cartia is an enteric coated aspirin product in 
Israel, Australia, New Zealand, and Hong Kong.  
In the US Cartia XT is extended release diltiazem.  
US and Canadian OTC brand name extensions 
create confusion due to the practice of reusing 
OTC brand names for products with different 
ingredients.  Unisom in the US and Canada 
contains doxylamine whereas Unisom SleepGels 
contain diphenhydramine as marketed in both 
countries.3 
Currently there is no international body that 
oversees brand name selection by pharmaceutical 
manufacturers.  The World Health Organization 
has established general principles for devising 
international nonproprietary names for 
pharmaceuticals.5  They also maintain 
international monographs for pharmaceutical 
substances.6  Proprietary name regulation will be 
another major area for international observation, 
control, and safety.   
As noted by the ISMP, brand name differences 
in foreign countries are one problem but so are 
differences in dosage forms for the same generic 
with their suffix listings.  Drug dosage form 
release characteristics, as represented by the brand 
name suffix (XR, LA, XL, etc.) vary and can cause 
patients to receive too much or too little of an out-
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of-country obtained medication.  There is no 
international nomenclature standard for release 
characteristics.2   
Look-alike and sound-alike brand name drug 
lists are readily available in the US and Canada.   
There is a great potential for patient safety 
problems with foreign look-alike and sound-alike 
brand names.  Unisomnia in Great Britain is a 
benzodiazepine, nitrazepam, used for insomnia.4  
Nitrazepam’s brand name is Sonotrat in Brazil.  
When written, it might be confused with Sonata 
(zaleplon) also used for insomnia in the US and 
Canada.4  Trexall is methotrexate in the US but 
Trexan is naltrexone in Italy.  Amyben, available 
in the United Kingdom, is amiodarone.  If this 
were dispensed for the sedative, Ambien 
(zolpidem) a significant adverse event could 
occur.2  Trental is pentoxifylline in the US and 
Canada.  Trentadil is bamifylline, a 
bronchodilator, in France.4  The antipsychotic, 
Prolixin, (fluphenazine) might look like and 
sound like Prolixan (azapropazone), a non-
steroidal anti-inflammatory agent, used in some 
European countries.4  International cautionary lists 
do not exist at this time for brand names.   
 
Advice 
Patients who are traveling abroad should have 
a complete list of their medications with both 
brand and generic names including the brand 
dosage form, dosage, use frequency, and purpose 
of use.  They should bring a sufficient supply of 
their medications in labeled bottles or packages 
with allowances for unexpected travel delays.  
Should they need a refill, remind them to actively 
check the generic name, dosage form, and 
strength to confirm a match.  If they are ordering 
medication from an internet pharmacy they should 
ask their prescriber to clearly write this same 
information on the prescription.   
Healthcare professionals needing information 
on imported or foreign country medications may 
find references such as the Micromedex products, 
Martindale: The Complete Drug Reference and 
Index Nominum International Drug Directory, 
helpful.  Lexi-Comp’s Lexi-Drugs International is 
an additional source. 
Drug information or poison control centers in 
the US can be contacted for help.  In the US the 
national toll-free number is: 800-222-1222.  The 
American Association of Poison Control Centers 
maintains a complete list of poison control 
centers.  They include centers in Canada, New 
Zealand, Australia, and Puerto Rico.  Their 
website can be found at: 
http://www.aapcc.org/findyour.htm.  In Canada, a 
list of poison control centers can be found at: 
http://www.capcc.com or http://www.napra.org/ 
practice/Toolkits/Toolkit6/poison_control.html.  
Be aware that every center may not be able to 
immediately answer a question, unless it is of an 
emergency basis. 
Encourage reporting of potential product 
problems or actual occurrences.  To report product 
problems in the US, call the FDA MEDWATCH 
program at 1-800-FDA-1088. The MEDWATCH 
program is also available on-line at 
www.fda.gov/medwatch.  Or report to the USP 
Medication Errors Reporting Program in 
cooperation with the Institute for Safe Medication 
Practices at 1-800-23-ERROR or at 
www.usp.org/patientSafety/reporting/mer.html.  
In Canada, call the Canadian Adverse Drug 
Reaction Monitoring Program at 1-866-234-2345.  
The Canadian adverse reaction reporting form can 
be found at: http://www.hc-sc.gc.ca/hpfb-
dgpsa/tpd-dpt/adverse_e.pdf.  It should be 
completed and faxed to 1-866-678-6789.  You can 
also contact the Institute for Safe Medication 
Practices (ISMP) by calling 215-947-7797 or 





Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
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